Biotherapeutic products represent a new therapeutic revolution in disease treatment and are by far the fastest-growing segment of the pharmaceutical industry – yet the recent biosimilar guidelines issued by the World Health Organization (WHO) are myopic, inconsistent or vague about some well-established scientific issues Biosimilar products include recombinant proteins and hormones, monoclonal antibodies (mAbs), cytokines, […] Continue reading ->
Infectious diseases like HIV, tuberculosis and malaria have long been the biggest public health challenges in low- and middle-income countries (LMICs) but over the past decade, non-communicable diseases (NCDs) have risen at an alarming rate. While every country faces a growing NCD burden, low- and middle-income countries are seeing the fastest increase. This epidemiological shift […] Continue reading ->
Recently, the Coalition for Epidemic Preparedness (CEPI) launched a $3.5 billion plan of investment in ground-breaking R&D, linked to equitable access commitments, which aims to transform the world’s ability to respond to new epidemic and pandemic threats and catalyze cooperation across a coalition of public and private sector partners. As parliamentarians from across the European […] Continue reading ->
Should the corporate sector be allowed to engage in negotiations around the new binding instrument on pandemic prevention, preparedness and response that is being developed by World Health Organization member states? This week’s closed-door debate by WHO member states to decide who should get a seat around the table risks opening a Pandora’s box of […] Continue reading ->
The wider use of pooled procurement in national health systems can help low- and middle-income countries get a better deal on pharmaceuticals – here’s how and why. Low- and middle-income countries are making strides in bolstering their domestic pharmaceutical sectors—evidenced by the recent deal between South Africa’s Afrigen Biologics and Belgium’s Univercells, to develop the […] Continue reading ->